Introduction
============

Each year, *NHS Evidence - skin disorders*(a national specialist library funded by NICE, available at <http://www.library.nhs.uk/skin>) publishes an Annual Evidence Update on Acne Vulgaris, which is a search for new evidence published or indexed in the last year \[[@B1]\]. NHS Evidence - skin disorders also produces Annual Evidence Updates on atopic eczema, psoriasis and skin cancer. The purpose is to make our community of clinical users (mainly dermatologists, general practitioners and nurses) aware of newly published research studies, to discuss their significance for clinical practice, and to warn of any methodological issues in their interpretation.

The Annual Evidence Updates normally search for systematic reviews and guidelines, because of the potential hazards in commenting on single randomized controlled trials or RCTs \[[@B2]\]. However, as only one systematic review on acne was found for our 2009 Annual Evidence Update, which was published on 2^nd^March 2009, we also searched for new RCTs published or indexed over the previous year since the last Annual Evidence Update \[[@B1],[@B3]\]. A full description of the methodology and search strategies used can be found on the Annual Evidence Update web pages \[[@B1]\].

The RCTs that were found for the 2009 Annual Evidence Update comprise a \"spot check\" of acne trials published over a one year period. In the course of putting together the Annual Evidence Update \[[@B1],[@B3]\] the authors were struck by a high frequency of problems in the reporting and interpretation of these acne RCTs, which are now highlighted in this article. Our perspective in this commentary is not to condemn well-intentioned authors but to highlight common problems that may not be immediately obvious to a wider readership in the hope of reducing bias, improving patient welfare and influencing the future conduct and reporting of clinical trials on acne. The problems highlighted in this commentary are not restricted to acne trials and we hope that the examples given will help to provide further evidence for the need to improve standards in the reporting of all clinical trials.

Discussion
==========

From the 25 RCTs found for the 2009 Annual Evidence Update, at least 12 major problems of trial reporting were identified; these are listed in Table [1](#T1){ref-type="table"} in the order in which the trials appeared in the Update \[[@B1]\].

###### 

Common problems in the reporting of acne trials

  Problem                                                                                Description                                                                                                                                         References
  -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  1\. Insufficient power                                                                 Underpowered trials can produce false negative results in superiority studies or incorrect claims of equivalence                                    Pediatric Dermatology \[[@B4]\]; Indian Journal of Dermatology, Venereology and Leprology \[[@B5]\]
  2\. Duplicate publication                                                              Publication of the same trial more than once can artificially enhance its impact and distort subsequent meta-analyses                               American Journal of Clinical Nutrition \[[@B8]\]; Journal of the American Academy of Dermatology \[[@B9]\]; Contraception \[[@B11]\]; Cutis \[[@B12]\]
  3\. Incorrect statistical comparison                                                   A \"within-groups\" comparison from baseline may give positive results when the correct \"between-groups\" comparison is negative                   Archives of Dermatology \[[@B15]\]; Saudi Medical Journal \[[@B16]\]
  4\. \"Salami publication\"                                                             Splitting the results from a single trial to produce more than one publication can artificially increase its impact                                 Journal of Drugs in Dermatology \[[@B19],[@B20]\]
  5\. Inferiority margin not pre-specified                                               In non-inferiority studies, lack of a pre-specified inferiority margin means that the margin might have been chosen in retrospect to fit the data   Journal of Drugs in Dermatology \[[@B19],[@B20]\]
  6\. Two independent trials combined and reported as one                                Independent trials should be analysed and reported separately before combination in any subsequent meta-analysis                                    Cutis \[[@B22]\]; Journal of the American Academy of Dermatology \[[@B23]\]
  7\. Loss of masking due to trial therapies not considered in \"double-blind\" trials   Comparators with different physical characteristics or adverse effect profiles can cause loss of participant or investigator masking                European Journal of Dermatology\[[@B25]\]; International Journal of Cosmetic Science \[[@B26]\]
  8\. Stating P values without publishing outcome data                                   P values can be misleading without confidence intervals and original outcome data                                                                   Indian Journal of Dermatology \[[@B27]\]
  9\. Failure to account for all randomized participants                                 Absence of an intention-to-treat analysis raises the possibility of attrition bias due to loss of study participants before the primary endpoint    International Journal of Cosmetic Science \[[@B26]\]
  10\. Selective outcome reporting                                                       Multiple endpoints, rather than a single primary endpoint, allow \"data fishing\" in which only the positive outcomes are highlighted               Journal of Drugs in Dermatology \[[@B28]\]
  11\. Treatment effects statistically significant but clinically insignificant          Highly significant P values may mask a small improvement in disease severity that is insufficient to be of clinical benefit to patients             Journal of Drugs in Dermatology \[[@B29]\]
  12\. Odds ratios used to exaggerate treatment effect                                   Odds ratios can be misleadingly large when event rates are high - rate ratios give more understandable results                                      Contraception \[[@B11]\]

Lack of power
-------------

The first problem identified was RCTs being insufficiently powered to provide evidence of no difference between trial interventions. One study \[[@B4]\], designed to assess the effect of exercise on acne, randomized a total of 30 teenage boys to avoid or perform exercise, and the latter group was further divided into those who showered 1 hour or 4 hours later. The small numbers in the three groups produced very wide confidence intervals that illustrated the underpowered nature of the study. It was reported as a pilot study but a power calculation had been performed. A second study \[[@B5]\] which recruited 60 subjects claimed equivalence between an oral acne therapy and the same treatment in combination with topical agents. However, an equivalence margin was not determined in advance and the equivalence claim was made on the basis of non-significant tests for superiority, a problem frequently encountered in clinical trial reporting \[[@B6]\]. In essence, no evidence of an effect had been misinterpreted as evidence of no effect.

Duplicate publication
---------------------

There were two sets of duplicate publications, in which the same trial was published more than once, identified in the 2009 Annual Evidence Update. The first \[[@B7]\] was an additional analysis in a subgroup of patients from a trial on low glycaemic load for treating acne that had already been reported twice. The original duplicate publications \[[@B8],[@B9]\] had been picked up by the 2008 Annual Evidence Update \[[@B10]\]; the papers reported the same trial but failed to cross-reference each other and the journal editors had not been informed. In the second set of duplicate publications, primary efficacy outcomes were presented in one paper \[[@B11]\] without indicating the presence of secondary efficacy outcomes, with the latter then being presented in a second paper four months later \[[@B12]\]. The secondary efficacy variables were similar to the primary variables and showed similar results. We believe that all relevant trial results (especially efficacy results) should be presented in one paper. If there are good reasons to split the results, the seminal index paper should make at least some reference to the measurement of other outcomes and whether there is a plan to publish them elsewhere. Several issues arise from duplicate publication. There could be distortion of any subsequent meta-analysis if the study results are counted twice - such a problem has already arisen with the duplicate publication on low glycaemic load \[[@B13]\]. In addition, journal copyright may be infringed, and multiple articles take up additional journal resources. It has also been demonstrated how duplicate publications result in higher citations \[[@B14]\].

Testing the wrong thing
-----------------------

Another pitfall that we picked up was the issue in a parallel group study of performing a \"within-groups\" comparison, rather than the correct \"between-groups\" analysis of change from baseline. In its abstract, a study that compared a computer presentation with a written information handout stated benefit in favour of the computer approach based on a within-groups comparison, despite a non-significant between-groups comparison in the main article text \[[@B15]\]. Another study of two topical treatments for active acne only performed a within-groups comparison \[[@B16]\], so no account was made for the effect of natural disease history, in particular regression to the mean. Whether such erroneous highlighting of results is deliberate or accidental is unclear - we suggest that it can be a ploy used by authors to try and \"save face\" in the light of an essentially inconclusive study, especially as some journal editors and clinicians will not spot the lack of a correct between-groups statistic.

\"Salami publication\" and absent inferiority margins
-----------------------------------------------------

\"Salami publication\" of a clinical trial involves splitting the results from a single trial into several packages that are then published separately and may artificially increase the impact of the study \[[@B17]\]. This issue affected a three-armed parallel groups study registered as a single trial on the *ClinicalTrials.gov*database \[[@B18]\]. Two of the treatment arms were separately compared with the third arm and each comparison was published as a stand-alone trial \[[@B19],[@B20]\], albeit in the same journal supplement. It would have been straightforward to report the results of all three arms in a single publication. Neither publication referenced the other. Another problem with the trial is that it was reported as a non-inferiority study but details of the 15% non-inferiority margin were not stated in the ClinicalTrials.gov register entry, so it is uncertain whether this margin was chosen prospectively or retrospectively. We also found an acne study that compared the same antibiotic at a low dose compared with the standard dose for acne which was essentially a non-inferiority trial, but no non-inferiority margin was specified \[[@B21]\].

Reporting two independent studies as one
----------------------------------------

Almost the reverse of duplicate publication is pooling the results of more than one previously unpublished, independent clinical trial in a combined analysis, rather than reporting the results separately. Under such circumstances, the larger, combined analysis could produce a significant result when individually the trials fail to reach significance. Two pairs of RCTs combined in single analyses were spotted in the Annual Evidence Update \[[@B22],[@B23]\]. Results of the individual, independent studies were not presented separately. In both cases these were industry-funded studies of novel topical preparations conducted in North America. It is presumed that two identical RCTs were needed for FDA licensing approval. Whilst it is sometimes appropriate to combine similar studies using a formal meta-analytical approach, we suggest that it is inappropriate to only present combined results in the primary publication of two pivotal RCTs \[[@B24]\].

Were they really \"double-blind\"?
----------------------------------

In RCTs of topical therapy, particular care is needed to ensure that the comparator preparations closely resemble each other, to prevent loss of participant or investigator masking. In placebo-controlled studies the ideal comparator is the vehicle used for the active treatment, but this is not necessarily possible in head-to-head studies of two active treatments. One trial was reported to be \"double-blind\" but it compared an acne cream with a gel \[[@B25]\], which would differ in appearance and properties on the skin. Another common reason for loss of blinding in RCTs is a frequent adverse effect associated with one of the treatments and not the other. In topical acne therapy, skin irritation often differs between preparations and this probably caused some loss of blinding in a topical retinoid trial reported to be double-blind \[[@B26]\].

Absent data and missing patients
--------------------------------

Good practice in trial reporting is concerned with providing as much original trial data as possible. Confidence intervals are needed as well as just P values. Unfortunately, one efficacy study failed to provide any trial data and relied on stating P values along with a potentially unrepresentative selection of clinical photographs \[[@B27]\]. Another issue of good practice with RCT reporting is to account for all the patients randomized to prevent attrition bias, with an intention-to-treat analysis and a pre-specified method to deal with missing values. One trial randomized 45 participants but included data for only 30 of them at the final 8 week endpoint; no data or explanation were given about those participants who dropped out of the study \[[@B26]\].

Data fishing, impressive P values, and \"plumped up\" odds ratios
-----------------------------------------------------------------

There are several ways in which a trial report can make the results appear more impressive than they really are. One of these is to \"data fish\" amongst a large number of outcomes, rather than focus on a single, pre-specified primary outcome. This was probably the case in an acne trial that displayed only its positive outcomes in the abstract \[[@B28]\]. Another issue is reliance on a statistically significant effect that may be insignificant in clinical practice. An impressive P value of 0.001 was used to justify the efficacy of an acne therapy \[[@B29]\], but this equated to only a modest 11% reduction in the acne lesion count, which probably would not be meaningful to a patient. Finally, use of more impressive sounding odds ratios rather than rate ratios was spotted \[[@B11]\] which will give an overestimate when event rates are frequent \[[@B30]\].

Conclusion
==========

One of the foundations of evidence-based practice is the availability of high quality evidence on which to base clinical decisions. Although some of the trials found in the Annual Evidence Update were reported to a high standard, around a half contained potentially serious reporting problems and framing biases that could mislead the clinical readership.

Many of the problems outlined in this article could have been avoided by adherence to the CONSORT guidelines \[[@B31]\] and prospective trial registration. CONSORT has provided the gold standard for RCT reporting, and adoption of the guidelines by many, but not all, journals has ensured a standardized method of quality control. The CONSORT list can also be used to aid trial design at the planning stage. Prospective trial registration on a public clinical trials database, or publication of the study protocol, is also very helpful for subsequent users of research to ensure that primary endpoints are stated prospectively. In essence, the study designers are asked to \"nail their flag to the mast\" in advance in terms of their most important endpoint. Again, adoption of this as a requirement for publication by journals has helped to promote its use.
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